Sofia’s Hope, Inc. is committed to making a difference in the world of pediatric cancer and specifically in the world of pediatric cardio-oncology. Sofia did not die from non-Hodgkin’s lymphoma but from the long-term effects of the chemotherapeutic treatments she received as a child. The anthracycline medication Sofia received (used in over 50% of current pediatric cancer protocols) gave her over eight more years of life but it also damaged her heart beyond repair.
While research has lead to the availability of a cardio-protective medication called dexrazoxane, its use will only become mandatory in new protocols beginning in 2018. In the meantime, children diagnosed with cancer will continue to receive anthracyclines as they have been for more than four decades. And they will continue to save lives but for many children it will only be temporary. As such, THE NEED FOR RESEARCH IN THIS AREA IS ESSENTIALl!! Specifically, researchers need help in:
- Understanding how dexrazoxane works and how its use can be extended to all protocols;
- Determining proper dosage of dexrazoxane in protocols with high doses of anthracyclines;
- Developing new ways to diagnose potential cardiac issues as early as possible;
- Improving and developing new therapies to treat their heart failure when it occurs; and
- Further understanding why some children’s hearts are negatively affected while others not (genetic research).
Sofia’s Hope is proud to announce that we are committed to helping fund a Clinical Research Coordinator for Dr. Steven Lipshultz, currently at the Wayne State University School of Medicine’s Department of Pediatrics and the Children’s Research Center of Michigan at the Children’s Hospital of Michigan, and the world’s expert on pediatric cardio-oncology. His work has been instrumental in this area and has resulted in positive outcomes for many children and their families. However, he still has a lot of work ahead and to be as effective and efficient as possible he needs our support in funding a Clinical Research Coordinator focused on pediatric cardio-oncology.